




PATENT
ATTORNEY DOCKET NO. 04843/113003

Certificate of Mailing: Date of Deposit: September 30, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Teicher et al. Art Unit: 1654
Serial No.: 10/646,063 Examiner: Marcela M. Cordero
Garcia
Filed: August 22, 2003 Customer No.: 21559
Title: CORTICOSTEROID CONJUGATES AND USES THEREOF

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the

10/04/2005 LWONDIMI 00000024 10646063

03 FC:1806

180.00 OP

mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: Sept 30, 2005



Paul T. Clark

Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Jeffrey J. Ellison, Reg. No. 51,649
for Paul T. Clark



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	04843/113003
	Serial No.	10/646,063
	Applicant	Martin H. Teicher et al.
	Filing Date	August 22, 2003
	Group	1654
	IDS Filed	September 30, 2005
Customer No.	21559	

U.S. PATENT DOCUMENTS						
Examiner=s Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,427,649	01/24/1984	Dingle et al.			
	4,443,440	04/17/1984	Anderson et al.			
	4,456,602	06/26/1984	Anderson et al.			
	4,609,496	09/02/1986	Eisenbrand et al.			
	4,469,689	09/04/1984	Anderson et al.			
	4,472,392	09/18/1984	Anderson et al.			
	4,678,609	07/07/1987	Engels, Joachim			
	4,948,533	08/14/1990	Braughler et al.			
	5,338,837	08/16/1994	Kahne, Daniel E.			
	5,571,795	11/05/1996	Kahne et al.			
	5,599,807	02/04/1997	Ogata et al.			
	5,614,514	03/25/1997	Axelsson et al.			
	5,627,270	05/06/1997	Kahne et al.			
	5,674,861	10/07/1997	Anderson et al.			
	5,693,769	12/02/1997	Kahne et al.			
	5,762,918	06/09/1998	Thorpe, Philip E.			
	5,888,995	03/30/1999	Axelsson et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner=s Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	04843/113003
	Serial No.	10/646,063
	Applicant	Martin H. Teicher et al.
	Filing Date	August 22, 2003
	Group	1654
	IDS Filed	September 30, 2005
Customer No.	21559	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Welinder, K., "Amino acid sequence studies of horseradish peroxidase. Tryptic glycopeptide containing two histidine residues and a disulfide bridge," <i>FEBS Letters</i> 30(2):243 (1973).
	Krupin et al., "Topical corticosteroid therapy and pituitary-adrenal function," <i>Arch. Ophthalmol.</i> 94(6):919 (1976).
	Miyabo et al., "A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man," <i>Eur. J. Clin. Pharmacol.</i> 20(4):277 (1981).
	Petersen et al., "Pharmacokinetics of betamethasone in healthy adults after intravenous administration," <i>Eur. J. Clin. Pharmacol.</i> 25(5):643 (1983).
	Eryomin et al., "Interaction of steroid-peroxidase conjugates with cellulose immunosorbants in aqueous and micellar media," <i>Biochemistry (Moscow)</i> 63(10):1148 (1998).
	Brown et al., "Hippocampal remodeling and damage by corticosteroids: implications for mood disorders," <i>Neuropsychopharmacology</i> 21(4):474 (1999).
	Killian et al., "Modulating blood-brain barrier interactions of amino acid-based anticancer agents," <i>Drug Delivery</i> 7(1):21 (2000).
	Haynes et al., "Dexamethasone induces limited apoptosis and extensive sublethal damage to specific subregions of the striatum and hippocampus: implications for mood disorders," <i>Neuroscience</i> 104(1):57 (2001).
	Rossi et al., "Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease," <i>Biotechnol. Appl. Biochem.</i> 33(Pt 2):85 (2001).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	